School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Anavex Life Sciences Corp. AVXL

Healthcare · Biotechnology

$1.49last close 2026-10-09 · market cap $138.12M · delayed data

Trailing returns

1M-45.82%
3M-44.81%
6M-51.15%
1Y-84.35%
5Y-91.35%

Basis: Adjusted daily closes.

What it does

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer .

Open AVXL in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies